



Commercial/Healthcare Exchange PA Criteria

Effective: November 2015

Prior Authorization: Long-acting muscarinic antagonists

Products Affected: Seebri Neohaler (glycopyrrolate) Oral Inhalation Capsule

Medication Description: Respiratory antimuscarinic or long-acting muscarinic antagonist (LAMA), which are often referred to as anticholinergics. Bronchodilation occurs through inhibition of the M3 receptor in the smooth muscle of the airways. Antimuscarinic anticholinergic agents inhibit the action of acetylcholine at autonomic effectors innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine, but lack cholinergic innervation.

Covered Uses: Chronic obstructive pulmonary disease (COPD)

Exclusion Criteria: N/A

Required Medical Information:

1. Diagnosis
2. Previous medications tried/failed

Age Restrictions: 18 years of age and older

Prescriber Restrictions: N/A

Coverage Duration: 12 months

Other Criteria:

- A. Patient has a diagnosis of COPD; AND
- B. Patient has had a documented trial and failure of Spiriva/Spiriva Respimat AND Incruse Ellipta.

References:

1. Product Information: SEEBRI(TM) NEOHALER(R) oral inhalation powder, glycopyrrolate oral inhalation powder. Novartis Pharmaceuticals Corporation (per manufacturer), East Hanover, NJ, 2015.
2. Product Information: INCRUSE ELLIPTA oral inhalation powder, umeclidinium oral inhalation powder. GlaxoSmithKline (per FDA), Research Triangle Park, NC, 2019.

Last Rev. March 2020

Revision History:

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	11/2015
2	Policy Update	Removed Affected products from CCI Freedom Inhaler Policy and renamed policy, adopted EH Template; CCI P&T Review History: 11/15, 2/16, 11/16, 5/17, 8/17, 11/17, 11/18 CCI Revision Record: 1/16, 11/16, 5/17, 8/17, 11/17, 1/18, 9/18; 11/19	All	1/13/2020
3	Update	Remove Incruse Ellipta (umeclidinium) Inhalation as target and add as preferred agent	Products Affected Other Criteria	3/27/2020